ACADIA Pharmaceuticals Inc. (ACAD)

NMS – Real Time Price. Currency in USD

29.42

+0.01 (0.05%)

Market open: Aug 12, 2026, 11:15 AM EDT

29.99

+0.58 (1.97%)

Previous after-hours: Aug 11, 2026, 7:39 PM EDT

07.08.2026

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Here is how Acadia Pharmaceuticals (ACAD) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.

06.08.2026

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

Acadia Pharmaceuticals (ACAD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

06.08.2026

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

As investors look to balance growth opportunities with defensive positioning, Acadia Pharmaceuticals, CVS Health, and Eli Lilly stand out as healthcare names combining resilient business models with strong earnings momentum.

05.08.2026

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

Acadia beats Q2 earnings and revenue estimates as strong Daybue and Nuplazid sales lift results and prompt the company to raise its 2026 revenue outlook.

05.08.2026

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

04.08.2026

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

Acadia Pharmaceuticals (ACAD) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.16 per share a year ago.

04.08.2026

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

ACADIA Pharmaceuticals NASDAQ: ACAD reported second-quarter 2026 revenue of $308 million, representing 17% year-over-year growth on an adjusted basis, as sales of its Rett syndrome therapy DAYBUE and Parkinson's disease psychosis treatment NUPLAZID increased.

Videos

No Data

There is no data to display

Press releases

04.08.2026

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2026. “Acadia delivered an outstanding second quarter, highlighted by strong commercial execution across both DAYBUE and NUPLAZID, resulting in total revenue growth of 17% year-over-year on an adjusted basis,” said Catherine Owen Adams, Chief Executive Officer of Acadia. “For DAYBUE, continued patient demand and robust uptake of STIX drove another q.

ACADIA Pharmaceuticals Inc. (ACAD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ACADIA Pharmaceuticals Inc. (ACAD)

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

Videos

No Data

Press releases

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

Videos

No Data

Press releases

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Search stocks

ACADIA Pharmaceuticals Inc. (ACAD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

ACADIA Pharmaceuticals Inc. (ACAD)

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

Videos

No Data

Press releases

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results

Is ACADIA Pharmaceuticals (ACAD) Outperforming Other Medical Stocks This Year?

Can Acadia (ACAD) Run Higher on Rising Earnings Estimates?

3 Medical Stocks Standing Out After Crushing Q2 Earnings Expectations

ACAD Q2 Earnings and Revenues Beat, '26 View Raised on Product Sales

ACADIA Pharmaceuticals Inc. (ACAD) Q2 2026 Earnings Call Transcript

Acadia Pharmaceuticals (ACAD) Q2 Earnings and Revenues Beat Estimates

ACADIA Pharmaceuticals Q2 Earnings Call Highlights

Videos

No Data

Press releases

Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results